NCT03970031View on ClinicalTrials.gov

A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

PHASE3UnknownINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Type2 DiabetesNASH - Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease
Interventions
DRUG

MSDC-0602K

MSDC-0602K tablet

DRUG

Placebo

Matching tablet

Sponsors
All Listed Sponsors
lead

Cirius Therapeutics, Inc.

INDUSTRY

NCT03970031 - A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH | Biotech Hunter | Biotech Hunter